The transition from a fetus to a newborn is the most complex physiologic adaptation that
occurs in human experience. Before medicalization of delivery, the transition had to occur …

Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …

Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed
circulatory adaptation at birth, seen in about 2/1000 live born infants. While it is mostly seen …

Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …

Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway.
On binding of NO to its prosthetic haem group, sGC catalyses the synthesis of the second …

Alterations of the nitric oxide receptor, soluble guanylate cyclase (sGC) may contribute to the
pathophysiology of pulmonary arterial hypertension (PAH). In the present study, the …

The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …

The pulmonary circulation rapidly adapts at birth to establish lungs as the site of gas
exchange. Abnormal transition at birth and/or parenchymal lung disease can result in …

Nitric oxide (NO) activates soluble guanylate cyclase (sGC) by binding its prosthetic heme
group, thereby catalyzing cyclic guanosine monophosphate (cGMP) synthesis. cGMP …